TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24237610
Drug: EP42675 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP42675 (5 mg, single dose) + Aspirin (100 mg) + Clopidogrel (75 mg)
Study: 24237610
Drug: EP42675 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP42675 (5 mg, second dose) + UFH (30 or 60 IU kg(‐1))
Study: 24237610
Drug: EP42675 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP42675 (5 mg, single dose)
Study: 15959362
Drug: Control (nonoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nonoperative treatment)
Study: 12030727
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 6 mg
Study: 9849982
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml intradermal (i.d.) PVRV
Study: 9849982
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml intramuscular (i.m.) PVRV
Study: 7852216
Drug: recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant erythropoietin (rhEPO) therapy
Study: 3214852
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1.0 mM copper and 2.0 mM hexetidine
Study: 23747945
Drug: 1.0mg fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0mg fluoride tablet daily
Study: 16709309
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Atorvastatin + Fenofibrate)
Study: 16709309
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Combination treatment
Study: 8492101
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b therapy for 1 year
Study: 8492101
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy for 1 year
Study: 6428307
Drug: Rosoxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosoxacin (300 mg oral dose)
Study: 6428307
Drug: Ampicillin (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (3.5 g) plus Probenecid (1 g)
Study: 22752356
Drug: No propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No propofol infusion
Study: 17493508
Drug: Cilazapril 2.5-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5-5.0 mg/day (n=70)
Study: 17493508
Drug: Enalapril 10-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-20 mg/day (n=82)
Study: 17493508
Drug: Perindopril 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4-8 mg/day (n=73)
Study: 17493508
Drug: Imidapril 10-20
Normalized name: imidapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10-20 mg/day (n=76)
Study: 17375736
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization (OD) for milk allergy
Study: 17375736
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization (OD) for egg allergy
Study: 15037408
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHEA
Study: 8958491
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with adrenaline 5 micrograms mL‐1 (group II)
Study: 8958491
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with adrenaline 1.66 micrograms mL‐1 (group III)
Study: 3883504
Drug: oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral etoposide (VePe-sid) 300 mg/m2 on days 1 and 2 for 6 cycles
Study: 3883504
Drug: oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral etoposide plus cyclophosphamide 300 mg/m2 IV on days 1 and 2 for 6 cycles
Study: 3883504
Drug: oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral etoposide
Study: 31415133
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment (3 hours paediatrician + 4 hours dietician)
Study: 31415133
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment (35 hours with a multidisciplinary team)
Study: 25735985
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2) at 2.4 standard atmosphere, FI O2 = 1.0, for 90 minutes
Study: 21061834
Drug: Olmesartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (40 mg/day)
Study: 20137542
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg/day)
Study: 12908850
Drug: Rebif 44
Normalized name: Rebif 44 MCG in 0.5 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebif 44 microg three times weekly
Study: 10999649
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal GTN therapy (0.6 mg/hour)
Study: 10999649
Drug: Sublingual GTN
Normalized name: GTN Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual GTN (0.6 mg)
Study: 9360173
Drug: Manual border
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual border tracing by two observers or twice by the same observer
Study: 31522033
Drug: Brivanib 800
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib 800 mg daily
Study: 11794192
Drug: Warfarin (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted to produce an INR of 1.4 to 2.8)
Study: 22551105
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg per day)
Study: 31231918
Drug: Sufentanil 0.2
Normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.2 μg/kg (Group A)
Study: 31231918
Drug: Sufentanil 0.1
Normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.1 μg/kg (Group B)
Study: 23624890
Drug: Once-daily (QD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (QD) oral mesalazine (1.5 to 2.25 g/d)
Study: 23624890
Drug: Three-times-daily (TID)
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times-daily (TID) oral mesalazine
Study: 16580905
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g) + Tropisetron (5 mg)
Study: 16580905
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g) + Granisetron (3 mg)
Study: 16580905
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g) + Placebo (saline solution)
Study: 12751271
Drug: Valdecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (40 mg bid)
Study: 12751271
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg tid)
Study: 9473972
Drug: Continuous concurrent
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous concurrent visual feedback during practice
Study: 6327758
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (400 mg)
Study: 3214945
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg)
Study: 29551675
Drug: ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor 90 mg twice per day for 2 years
Study: 29551675
Drug: aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 81 mg twice per day for 2 years
Study: 26934973
Drug: Daily Engagement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Engagement of Meaningful Activities (DEMA)
Study: 24507460
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (4,000 IU/d)
Study: 24507460
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D3 (600 IU/d)
Study: 23059774
Drug: Bevacizumab (BV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BV) maintenance therapy after induction with carboplatin and paclitaxel (CP)
Study: 17609910
Drug: Rukuaixiao Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rukuaixiao Tablet, 4 tablets orally thrice a day for 4 months
Study: 7882099
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg) parenterally twice daily for 10 days
Study: 2239131
Drug: Diazepam (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (rectal solution every 12 hours when temperature is 38.5 degrees C or more)
Study: 2239131
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (suppositories at times of fever)
Study: 6787702
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) 6 mg per day
Study: 25644033
Drug: Tramadol-acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol-acetaminophen
Study: 24308613
Drug: i.v. normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. normal saline (20 mL/kg) plus observation
Study: 22049950
Drug: Peppered injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppered injections
Study: 18832042
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 40 microg PGE1
Study: 18832042
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no trial medication)
Study: 10087818
Drug: Continuous PKF
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous PKF (propofol 2‐10 mg.kg‐1.h‐1, ketamine 240 micrograms.kg‐1.h‐1 and fentanyl 0.4 microgram.kg‐1.h‐1)
Study: 7553406
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg, single intravenous dose)
Study: 7553406
Drug: Metoclopramide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (2 mg/kg, multiple doses)
Study: 2111768
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) discontinuation
Study: 2111768
Drug: Valproate (VPA)
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate (VPA) discontinuation
Study: 2111768
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) discontinuation
Study: 2111768
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stable therapy)
Study: 415439
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 5-10 mmol phosphate (155-310 mg phosphorus) per 1000 kcal of nutrient solution during parenteral nutrition.
Study: 415439
Drug: Increased phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased phosphate dosage for hypophosphatemic patients with acute renal insufficiency.
Study: 415439
Drug: Serum phosphate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum phosphate determination at the start of parenteral nutrition and every second day during the first week.
Study: 415439
Drug: Serum phosphate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum phosphate determination twice weekly after the first week of parenteral nutrition.
Study: 21463068
Drug: Concurrent Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent Alcohol Dependence (AD)
Study: 16886934
Drug: Concurrent stress-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent stress-management therapy
Study: 16886934
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication and placebo (irrespective of drug condition)
Study: 16886934
Drug: Neurologists' ratings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurologists' ratings of improvement, participants' reports of improvement, daily headache recordings
Study: 15174784
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 200 microg twice daily
Study: 15174784
Drug: Treatment-free period
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free period
Study: 9475646
Drug: Placebo (cellulose‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose‐based placebo pills once a day for 2 weeks)
Study: 8560135
Drug: L-dopa 100-200
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa 100-200 mg
Study: 21930686
Drug: IMM-101 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM-101 0.1 mg (1 mg/ml)
Study: 21930686
Drug: IMM-101 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM-101 0.5 mg (5 mg/ml)
Study: 21930686
Drug: IMM-101 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM-101 1.0 mg (10 mg/ml)
Study: 21930686
Drug: IMM-101 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM-101 (all doses)
Study: 17655512
Drug: Alprazolam ODT
Normalized name: Alprazolam Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam ODT 1.0 mg under fasting conditions
Study: 17655512
Drug: Alprazolam ODT
Normalized name: Alprazolam Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam ODT 1.0 mg after a standard high-fat breakfast
Study: 12151926
Drug: ANH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANH group (5-8 ml/kg of blood withdrawn before systemic heparinization and replaced with colloid solutions)
Study: 20425223
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (rt-PA) administered within 4.5 hours of symptom onset
Study: 20425223
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (rt-PA) administered within 3 hours of symptom onset
Study: 17406114
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of treatment modalities
Study: 15750363
Drug: Herbal supplement
Normalized name: LYDIA PINKHAM Herbal Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal supplement for a 2-week period
Study: 15750363
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no herbal supplement)
Study: 11902251
Drug: Low-dose prostacyclin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostacyclin (2 ng/kg/min) added to the standard anesthetic protocol, started immediately before surgery and continued for a maximum of 48 hours.
Study: 11902251
Drug: Low-dose prostacyclin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostacyclin (2 ng/kg/min)
Study: 31401532
Drug: Tobacco/Menthol 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco/Menthol 36 mg/ml ECIG
Study: 31401532
Drug: Tobacco/Menthol 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco/Menthol 0 mg/ml ECIG
Study: 31401532
Drug: 36 mg/ml
Normalized name: iodine 36 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg/ml ECIG
Study: 29106497
Drug: Cumulative doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doxorubicin equivalent dose ≥268 mg/m2
Study: 10568767
Drug: Vaccinia-vectored vaccine;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinia-vectored vaccine; subcutaneous inoculation of approximately 10^7 plaque-forming units; administered in two doses at 4-week intervals.
Study: 10568767
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group); administered in a double-blinded manner.
Study: 3594319
Drug: No pre-medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-medication (control)
Study: 30541643
Drug: Selective brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective brain hypothermia (SBH) treatment
Study: 18073554
Drug: Medium-dose smoked
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose smoked cannabis (4% 9-delta-tetrahydrocannabinol)
Study: 18073554
Drug: High-dose smoked
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose smoked cannabis (8% 9-delta-tetrahydrocannabinol)
Study: 18073554
Drug: Low-dose smoked
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose smoked cannabis (2% 9-delta-tetrahydrocannabinol)
Study: 18073554
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of smoked cannabis
Study: 12351557
Drug: E(2) 2
Normalized name: (E)-2-butenedioic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 2 mg/day plus NETA 1 mg/day
Study: 27296057
Drug: Calcium-Vitamin D
Normalized name: Calcium-Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-Vitamin D (1000 mg calcium + 5000 IU vitamin D3)
Study: 27296057
Drug: Calcium-alone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-alone (1000 mg)
Study: 22063371
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 1mL.kg(‐1) as placebo
Study: 19808137
Drug: Flurbiprofen 50-mg
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50-mg orally disintegrating tablet (ODT)
Study: 19808137
Drug: Conventional flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional flurbiprofen 50-mg tablet
Study: 9558411
Drug: IdCSA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdCSA (1 mg/kg/d from day -1 to +20; n = 28)
Study: 9558411
Drug: IdCSA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdCSA + IdMTX (10 mg/m2 for day +1, 8 mg/m2 for days +3, +6, and +11; n = 32)
Study: 9522741
Drug: 5 commonly
Normalized name: Common timothy
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 commonly prescribed syrup medications
Study: 2574566
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol hydrochloride
Study: 1091822
Drug: Prazosin (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (3.0 to 7.5 mg per day)
Study: 1091822
Drug: Methyldopa or
Normalized name: methyldopa Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa or Propranolol (given in comparable doses)
Study: 25040636
Drug: Verbal education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal education based on an Australian National Prescribing Service patient leaflet regarding antibiotics
Study: 21331636
Drug: G-Coat Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Coat Plus (GP)
Study: 15111525
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet(12h))
Study: 15111525
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet(morn+bed))
Study: 15111525
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (pooled)
Study: 9589700
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg daily) for 6 months
Study: 8051377
Drug: Antibiotic prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylactic treatment including cephapirine, gentamicin and metronidazole
Study: 2522716
Drug: Heparin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (titrated to partial thromboplastin time 1.5 to 2.5 times normal) administered for 18 to 24 hours
Study: 2522716
Drug: Dextrose administered
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose administered for 18 to 24 hours
Study: 28484316
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25 percent bupivacaine + 5 mg morphine (0.5 mL) infiltrated in Group P
Study: 25271729
Drug: PK-guided individualized
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PK-guided individualized dosing of pazopanib
Study: 25271729
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of pazopanib (800 mg once daily)
Study: 18949545
Drug: Ruboxistaurin (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruboxistaurin (32 mg/day for 6 weeks)
Study: 9201803
Drug: Flumazenil (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (cumulative doses of 0.05, 0.10, 0.25, 0.50 and 1.00 mg at 15-min intervals)
Study: 1283061
Drug: Titrated, oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated, oral, double-blind, placebo-controlled challenge (DBPCFC) with fresh egg or milk